SCHEMBL27349689

SCHEMBL27349689

Cc1nnn(C[C@H](NC(=O)OC(C)(C)C)C(N)=O)c1C

nearest known ligand 0.37

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CTSK P43235 8/20 0.37
▸ CYP1A2 P05177 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ REN P00797 2/20 0.35
▸ CTSS P25774 4/20 0.35
▸ SCN9A Q15858 1/20 0.35
▸ ALDH1A1 P00352 2/20 0.34
▸ MAPT P10636 2/20 0.34
▸ CA1 P00915 1/20 0.34
▸ CA2 P00918 1/20 0.34
▸ CA7 P43166 1/20 0.34
▸ CTSL P07711 1/20 0.34
▸ CTSB P07858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30693749 0.89 PPARA (0.41) CTSKCYP1A2CYP2C9CYP2C19HTT
SCHEMBL27349682 0.88 CTSK (0.39) CTSKCYP1A2CYP2C9CYP2C19HTT
SCHEMBL27349797 0.78 APAF1 (0.50) RENALDH1A1MAPT
SCHEMBL18762457 0.72 CTSK (0.47) CTSKCYP1A2CYP2C9CYP2C19HTT
SCHEMBL18762459 0.72 CTSK (0.47) CTSKCYP1A2CYP2C9CYP2C19HTT
SCHEMBL8255549 0.72 CTSK (0.47) CTSKCYP1A2CYP2C9CYP2C19HTT
SCHEMBL31714029 0.71 PPARA (0.41) CTSKCTSSCTSLCTSB
SCHEMBL30693752 0.71 CYP19A1 (0.39) CTSKRENCTSSSCN9ACA1
SCHEMBL1534907 0.70 CTSK (0.47) CTSKCYP1A2CYP2C9CYP2C19HTT
SCHEMBL18925259 0.70 CTSK (0.58) CTSKCYP1A2CYP2C9CYP2C19HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376464-A1 Compounds for treatment a coronavirus infection TRAWSFYNYDD THERAPEUTICS INC (US) 2025-12-11 — — US disclosed
EP-4540227-A2 COMPOUNDS FOR TREATMENT A CORONAVIRUS INFECTION Trawsfynydd Therapeutics, Inc. (US) 2025-04-23 — — EP disclosed
WO-2023245162-A2 COMPOUNDS FOR TREATMENT A CORONAVIRUS INFECTION TRAWSFYNYDD THERAPEUTICS, INC. (US) 2023-12-21 — — WO disclosed
WO-2023245162-A2 COMPOUNDS FOR TREATMENT A CORONAVIRUS INFECTION TRAWSFYNYDD THERAPEUTICS, INC. (US) 2023-12-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376464-A1 Compounds for treatment a coronavirus infection ACE2, ACE, TMPRSS2 CTSK 85/4885CYP1A2 100/4885CYP2C9 191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback